Delcath Systems, Inc. Sponsors Satellite Session At World Meeting Of Melanoma/Skin Cancer Centers
06:30AM 11/24/09
Fund Manager Singles Out Hottest Commodity
The Encompass Fund, which has doubled in value this year, is staking its fortunes on a spike in uranium prices, driven by demand for nuclear energy.
05:00AM 10/20/09
Delcath Systems Treatment Gets Special FDA Status
Delcath Systems liver cancer drug candidate receives special designation by FDA
07:55AM 08/31/09
Seagate Chairman Buys $1.2M Worth
Jonathan Moreland, author of InsiderInsights, gives you the lowdown on top stock purchases and sales.
09:15AM 08/27/09
Delcath Systems Drug Gets Special FDA Designation
Delcath Systems cancer drug candidate receives additional special designation by FDA
09:11AM 06/02/09
Here's a look back at the hits, misses and notable moments from 2008.
12:20PM 12/29/08
Biotech Mailbag: NeurogesX Patchy at Best
It's not clear how this tiny biotech's pain patch can compete with a host of rivals, large and small.
01:01PM 12/05/08
Biotech Mailbag: NeurogesX Patchy at Best (RealMoney.com $)
It's not clear how this tiny biotech's pain patch can compete with a host of rivals, large and small.
07:00AM 12/05/08
Feuerstein's Biotech-Stock Mailbag: Delcath
More discussion of Sangamo's SB-509, revisiting Delcath and questioning YM Bio's chances with nimo.
10:03AM 06/27/08
Biotech-Stock Mailbag: Sangamo, YM Biosciences (RealMoney.com $)
More discussion of Sangamo's SB-509, revisiting Delcath and questioning YM Bio's chances with nimo.
07:03AM 06/27/08
Feuerstein's Biotech-Stock Mailbag
FDA is unlikely to reverse its earlier decision on Provenge.
10:55AM 12/15/07
Biotech Notebook: Xoma, Medivation, Delcath
Xoma's apparent lack of interest in a buyout may not serve investors in the near term.
02:50PM 11/27/07
Feuerstein's Biotech-Stock Mailbag
Pointing the finger at the FDA isn't a sound investment strategy.
11:40AM 11/03/07



Connect with TheStreet